<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02414477</url>
  </required_header>
  <id_info>
    <org_study_id>1501M60101</org_study_id>
    <nct_id>NCT02414477</nct_id>
  </id_info>
  <brief_title>Metabolism of Deuterated NNN in Smokeless Tobacco Users</brief_title>
  <official_title>Metabolism of Deuterated NNN in Smokeless Tobacco Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to better understand how people break down a tobacco specific
      cancer-causing toxin called N'-nitrosonornicotine (NNN) that is present in smokeless tobacco
      and cigarettes. Some people are able to get rid of this chemical as a harmless agent better
      than others. Through this research, the investigators hope to develop a better understanding
      of how people process potentially harmful chemicals and identify tobacco users who are in
      danger of developing cancer. Participants will complete questionnaires regarding their health
      and smoking history. The investigators will take blood samples, saliva samples, cheek cells
      and urine to measure exposure to toxins and harmful chemicals present in smokeless tobacco.
      Participants will be given smokeless tobacco study product and be asked to use only it for
      the entire time they are in the study. The study product contains deuterated NNN. Deuterated
      NNN is just like the NNN found in commercially available smokeless tobacco products, but is
      labeled with deuterium or heavy hydrogen atoms. Deuterium is non-toxic and safe. Using
      smokeless tobacco containing deuterium allows us to follow NNN as it is broken down in the
      body.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fifty healthy smokeless tobacco users will be recruited by advertising in Minneapolis-St.
      Paul area. This research will be conducted at the Tobacco Research Center at the University
      of Minnesota. Regular smokeless tobacco users will be screened over the phone. If eligible
      after the phone screen, participants will be invited to attend an orientation visit in the
      clinic where consent will be obtained and subjects will fill out forms about their tobacco
      use and medical history. Subjects who are determined to be eligible after the orientation
      visit will return to the clinic for a baseline visit where they will receive the smokeless
      tobacco product and be instructed to use only the study product until they return for their
      first lab session seven days later.

      Prior to each of the three lab sessions, subjects will collect all of their urine for the 24
      hours leading up to their scheduled appointment. At each lab session, participants will use
      the study product and collect their saliva and tobacco juices at regular intervals.
      Participants will also swab the inside of their cheek for cells and have their blood drawn.

      Collected samples will be used to characterize the metabolic activation and DNA binding of
      NNN.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine extent of α-hydroxylation of NNN as indicated by presence of keto acid 17 and hydroxy acid 22 in plasma</measure>
    <time_frame>One week post dosing</time_frame>
    <description>Deuterated NNN will be assessed after one week of regular use via smokeless tobacco study product, as well as during use in three lab sessions.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Tobacco Toxicant Exposure</condition>
  <arm_group>
    <arm_group_label>Smokeless tobacco study product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Smokeless tobacco product spiked with deuterated NNN.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deuterated NNN</intervention_name>
    <description>Smokeless tobacco study product</description>
    <arm_group_label>Smokeless tobacco study product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Regular smokeless tobacco user

          -  Good physical health with no unstable medical conditions

          -  Stable and good mental health, i.e., currently do not experience unstable or untreated
             psychiatric diagnosis, including substance abuse, as determined by the DSM-IV
             criteria, during the past six months

          -  Willing to perform study activities such as having blood sample drawn, saliva
             collection, urine collection, multiple clinic visits

          -  For female subjects of child bearing potential, not known to be pregnant or nursing,
             or planning to become pregnant within next 12 months

          -  Provide written informed consent

        Exclusion Criteria:

          -  Using other tobacco or nicotine containing products

          -  Unstable medical condition

          -  Currently taking any medications that affect relevant metabolic enzymes

          -  Not willing to use switch smokeless tobacco brand to use tobacco enriched with
             [pyridine-D4](S)-NNN for the course of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stephen S Hecht, Ph.D.</last_name>
    <phone>(612) 624-3869</phone>
    <email>hecht002@umn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Hecht, PhD</last_name>
      <phone>612-624-3869</phone>
      <email>hecht002@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Stepehn Hecht, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Boyle, P. and Levin, P. (2008) World Cancer Report, 2008. IARC, Lyon, FR.</citation>
  </reference>
  <reference>
    <citation>World Health Organization. (2012) Cancer Fact Sheet No. 297, February 2012 (http://www.who.int/mediacentre/factsheets/fs297/en/index.html).</citation>
  </reference>
  <reference>
    <citation>Fontham ET, Thun MJ, Ward E, Portier KM, Balch AJ, Delancey JO, Samet JM; ACS Cancer and the Environment Subcommittee. American Cancer Society perspectives on environmental factors and cancer. CA Cancer J Clin. 2009 Nov-Dec;59(6):343-51. doi: 10.3322/caac.20041. Epub 2009 Oct 28. Review. Erratum in: CA Cancer J Clin. 2010 Jan-Feb;60(1):62. Portier, Kenneth M [added].</citation>
    <PMID>19864396</PMID>
  </reference>
  <reference>
    <citation>Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.</citation>
    <PMID>23335087</PMID>
  </reference>
  <reference>
    <citation>Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):134.</citation>
    <PMID>21296855</PMID>
  </reference>
  <reference>
    <citation>International Agency for Research on Cancer (2012) Personal Habits and Indoor Combustions. In IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, v. 100E pp 43-167, IARC, Lyon, FR.</citation>
  </reference>
  <reference>
    <citation>Centers for Disease Control and Prevention (CDC). Current cigarette smoking among adults - United States, 2011. MMWR Morb Mortal Wkly Rep. 2012 Nov 9;61(44):889-94.</citation>
    <PMID>23134971</PMID>
  </reference>
  <reference>
    <citation>Shafey, O., Eriksen, M.P., Ross, H., and Mackay, J. (2009) The Tobacco Atlas, 3rd Edition. American Cancer Society and World Lung Foundation, Atlanta, GA.</citation>
  </reference>
  <reference>
    <citation>International Agency for Research on Cancer (2012) Personal Habits and Indoor Combustions. In IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, v. 100E pp 265-318, IARC, Lyon, FR.</citation>
  </reference>
  <reference>
    <citation>United States Department of Health and Human Services (2009) National Survey on Drug Use and Health. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Washington, D.C.</citation>
  </reference>
  <reference>
    <citation>International Agency for Research on Cancer (2007) Smokeless tobacco and tobacco-specific nitrosamines. In IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 89 pp 421-583, IARC, Lyon, FR.</citation>
  </reference>
  <reference>
    <citation>International Agency for Research on Cancer (2012) Personal Habits and Indoor Combustions. In IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, v. 100E pp 319-331, IARC, Lyon, FR.</citation>
  </reference>
  <reference>
    <citation>Fiore, M.C., Jaén, C.R., and Baker, T.B. (2008) Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. U.S. Department of Health and Human Services. Public Health Service., Rockville, MD.</citation>
  </reference>
  <reference>
    <citation>National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011 Aug 4;365(5):395-409. doi: 10.1056/NEJMoa1102873. Epub 2011 Jun 29.</citation>
    <PMID>21714641</PMID>
  </reference>
  <reference>
    <citation>Institute of Medicine (2012) Scientific Standards for Studies on Modified Risk Tobacco Products. National Academy Press, Washington, D.C.</citation>
  </reference>
  <reference>
    <citation>Surveillance Research Program, N. C. I. (2013) Fast Stats: An interactive tool for access to SEER cancer statistics. http://seer.cancer.gov/faststats (Accessed on 5-21-2013).</citation>
  </reference>
  <reference>
    <citation>American Nonsmokers' Rights Foundation. (2013) Percent of Population Covered by 100% Smokefree Restaurant AND Bar Laws. http://no-smoke.org/pdf/RBpercentMap. pdf .</citation>
  </reference>
  <reference>
    <citation>United States Department of Health and Human Services (2010) How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Ch. 5. U.S. Department of Health and Human Services, Washington, D.C.</citation>
  </reference>
  <reference>
    <citation>Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst. 1999 Jul 21;91(14):1194-210. Review.</citation>
    <PMID>10413421</PMID>
  </reference>
  <reference>
    <citation>Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K, Richardson D, Shepherd R, Small A, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A, Cahill DP, Louis DN, Goldstraw P, Nicholson AG, Brasseur F, Looijenga L, Weber BL, Chiew YE, DeFazio A, Greaves MF, Green AR, Campbell P, Birney E, Easton DF, Chenevix-Trench G, Tan MH, Khoo SK, Teh BT, Yuen ST, Leung SY, Wooster R, Futreal PA, Stratton MR. Patterns of somatic mutation in human cancer genomes. Nature. 2007 Mar 8;446(7132):153-8.</citation>
    <PMID>17344846</PMID>
  </reference>
  <reference>
    <citation>Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., Fulton, L., Fulton, R. S., Zhang, Q., Wendl, M. C., Lawrence, M. S., Larson, D. E., Chen, K., Dooling, D. J., Sabo, A., Hawes, A. C., Shen, H., Jhangiani, S. N., Lewis, L. R., Hall, O., Zhu, Y., Mathew, T., Ren, Y., Yao, J., Scherer, S. E., Clerc, K., Metcalf, G. A., Ng, B., Milosavljevic, A., Gonzalez-Garay, M. L., Osborne, J. R., Meyer, R., Shi, X., Tang, Y., Koboldt, D. C., Lin, L., Abbott, R., Miner, T. L., Pohl, C., Fewell, G., Haipek, C., Schmidt, H., Dunford-Shore, B. H., Kraja, A., Crosby, S. D., Sawyer, C. S., Vickery, T., Sander, S., Robinson, J., Winckler, W., Baldwin, J., Chirieac, L. R., Dutt, A., Fennell, T., Hanna, M., Johnson, B. E., Onofrio, R. C., Thomas, R. K., Tonon, G., Weir, B. A., Zhao, X., Ziaugra, L., Zody, M. C., Giordano, T., Orringer, M. B., Roth, J. A., Spitz, M. R., Wistuba, I. I., Ozenberger, B., Good, P. J., Chang, A. C., Beer, D. G., Watson, M. A., Ladanyi, M., Broderick, S., Yoshizawa, A., Travis, W. D., Pao, W., Province, M. A., Weinstock, G. M., Varmus, H. E., Gabriel, S. B., Lander, E. S., Gibbs, R. A., Meyerson, M., and Wilson, R. K. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075.</citation>
  </reference>
  <reference>
    <citation>Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, Jones D, Lin ML, Beare D, Lau KW, Greenman C, Varela I, Nik-Zainal S, Davies HR, Ordoñez GR, Mudie LJ, Latimer C, Edkins S, Stebbings L, Chen L, Jia M, Leroy C, Marshall J, Menzies A, Butler A, Teague JW, Mangion J, Sun YA, McLaughlin SF, Peckham HE, Tsung EF, Costa GL, Lee CC, Minna JD, Gazdar A, Birney E, Rhodes MD, McKernan KJ, Stratton MR, Futreal PA, Campbell PJ. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature. 2010 Jan 14;463(7278):184-90. doi: 10.1038/nature08629. Epub 2009 Dec 16.</citation>
    <PMID>20016488</PMID>
  </reference>
  <reference>
    <citation>Lee W, Jiang Z, Liu J, Haverty PM, Guan Y, Stinson J, Yue P, Zhang Y, Pant KP, Bhatt D, Ha C, Johnson S, Kennemer MI, Mohan S, Nazarenko I, Watanabe C, Sparks AB, Shames DS, Gentleman R, de Sauvage FJ, Stern H, Pandita A, Ballinger DG, Drmanac R, Modrusan Z, Seshagiri S, Zhang Z. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature. 2010 May 27;465(7297):473-7. doi: 10.1038/nature09004.</citation>
    <PMID>20505728</PMID>
  </reference>
  <reference>
    <citation>Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 2002 Oct 21;21(48):7435-51. Review.</citation>
    <PMID>12379884</PMID>
  </reference>
  <reference>
    <citation>Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, Maher CA, Fulton R, Fulton L, Wallis J, Chen K, Walker J, McDonald S, Bose R, Ornitz D, Xiong D, You M, Dooling DJ, Watson M, Mardis ER, Wilson RK. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012 Sep 14;150(6):1121-34. doi: 10.1016/j.cell.2012.08.024.</citation>
    <PMID>22980976</PMID>
  </reference>
  <reference>
    <citation>Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013 Mar 29;339(6127):1546-58. doi: 10.1126/science.1235122. Review.</citation>
    <PMID>23539594</PMID>
  </reference>
  <reference>
    <citation>Burns DM, Dybing E, Gray N, Hecht S, Anderson C, Sanner T, O'Connor R, Djordjevic M, Dresler C, Hainaut P, Jarvis M, Opperhuizen A, Straif K. Mandated lowering of toxicants in cigarette smoke: a description of the World Health Organization TobReg proposal. Tob Control. 2008 Apr;17(2):132-41. doi: 10.1136/tc.2007.024158.</citation>
    <PMID>18375736</PMID>
  </reference>
  <reference>
    <citation>U.S.Food and Drug Administration (2012) Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke; Established List. Fed. Regist. 77, 20034-20037.</citation>
  </reference>
  <reference>
    <citation>Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol. 1998 Jun;11(6):559-603. Review.</citation>
    <PMID>9625726</PMID>
  </reference>
  <reference>
    <citation>U.S.Department of Health and Human Services. (2013) National Toxicology Program. http://ntp.niehs.nih.gov/</citation>
  </reference>
  <reference>
    <citation>Vogel RI, Carmella SG, Stepanov I, Hatsukami DK, Hecht SS. The ratio of a urinary tobacco-specific lung carcinogen metabolite to cotinine is significantly higher in passive than in active smokers. Biomarkers. 2011 Sep;16(6):491-7. doi: 10.3109/1354750X.2011.598565. Epub 2011 Aug 3.</citation>
    <PMID>21812592</PMID>
  </reference>
  <reference>
    <citation>Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer. 2003 Oct;3(10):733-44. Review. Erratum in: Nat Rev Cancer. 2004 Jan;4(1):84.</citation>
    <PMID>14570033</PMID>
  </reference>
  <reference>
    <citation>Yuan JM, Gao YT, Murphy SE, Carmella SG, Wang R, Zhong Y, Moy KA, Davis AB, Tao L, Chen M, Han S, Nelson HH, Yu MC, Hecht SS. Urinary levels of cigarette smoke constituent metabolites are prospectively associated with lung cancer development in smokers. Cancer Res. 2011 Nov 1;71(21):6749-57. doi: 10.1158/0008-5472.CAN-11-0209. Epub 2011 Oct 25.</citation>
    <PMID>22028322</PMID>
  </reference>
  <reference>
    <citation>Yuan JM, Knezevich AD, Wang R, Gao YT, Hecht SS, Stepanov I. Urinary levels of the tobacco-specific carcinogen N'-nitrosonornicotine and its glucuronide are strongly associated with esophageal cancer risk in smokers. Carcinogenesis. 2011 Sep;32(9):1366-71. doi: 10.1093/carcin/bgr125. Epub 2011 Jul 6.</citation>
    <PMID>21734256</PMID>
  </reference>
  <reference>
    <citation>Hecht SS, Chen CB, Ornaf RM, Jacobs E, Adams JD, Hoffmann D. Reaction of nicotine and sodium nitrite: formation of nitrosamines and fragmentation of the pyrrolidine ring. J Org Chem. 1978 Jan 6;43(1):72-6.</citation>
    <PMID>619049</PMID>
  </reference>
  <reference>
    <citation>Hecht SS, Chen CB, Hirota N, Ornaf RM, Tso TC, Hoffmann D. Tobacco-specific nitrosamines: formation from nicotine in vitro and during tobacco curing and carcinogenicity in strain A mice. J Natl Cancer Inst. 1978 Apr;60(4):819-24.</citation>
    <PMID>633391</PMID>
  </reference>
  <reference>
    <citation>Hecht SS, Carmella SG, Murphy SE, Akerkar S, Brunnemann KD, Hoffmann D. A tobacco-specific lung carcinogen in the urine of men exposed to cigarette smoke. N Engl J Med. 1993 Nov 18;329(21):1543-6.</citation>
    <PMID>8413477</PMID>
  </reference>
  <reference>
    <citation>Carmella SG, Akerkar S, Hecht SS. Metabolites of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers' urine. Cancer Res. 1993 Feb 15;53(4):721-4.</citation>
    <PMID>8428352</PMID>
  </reference>
  <reference>
    <citation>Singer, B. and Grunberger, D. (1983) Molecular Biology of Mutagens and Carcinogens. Plenum Press, New York.</citation>
  </reference>
  <reference>
    <citation>Haglund J, Rafiq A, Ehrenberg L, Golding BT, Törnqvist M. Transalkylation of phosphotriesters using Cob(I)alamin: toward specific determination of DNA-phosphate adducts. Chem Res Toxicol. 2000 Apr;13(4):253-6.</citation>
    <PMID>10775324</PMID>
  </reference>
  <reference>
    <citation>Reynolds M, Peterson E, Quievryn G, Zhitkovich A. Human nucleotide excision repair efficiently removes chromium-DNA phosphate adducts and protects cells against chromate toxicity. J Biol Chem. 2004 Jul 16;279(29):30419-24. Epub 2004 Apr 15.</citation>
    <PMID>15087443</PMID>
  </reference>
  <reference>
    <citation>Haglund J, Van Dongen W, Lemière F, Esmans EL. Analysis of DNA-phosphate adducts in vitro using miniaturized LC-ESI-MS/MS and column switching: phosphotriesters and alkyl cobalamins. J Am Soc Mass Spectrom. 2004 Apr;15(4):593-606.</citation>
    <PMID>15047064</PMID>
  </reference>
  <reference>
    <citation>Beranek DT, Weis CC, Swenson DH. A comprehensive quantitative analysis of methylated and ethylated DNA using high pressure liquid chromatography. Carcinogenesis. 1980 Jul;1(7):595-606.</citation>
    <PMID>11219835</PMID>
  </reference>
  <reference>
    <citation>Haglund J, Henderson AP, Golding BT, Törnqvist M. Evidence for phosphate adducts in DNA from mice treated with 4-(N-Methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Chem Res Toxicol. 2002 Jun;15(6):773-9.</citation>
    <PMID>12067244</PMID>
  </reference>
  <reference>
    <citation>Zhang S, Wang M, Villalta PW, Lindgren BR, Lao Y, Hecht SS. Quantitation of pyridyloxobutyl DNA adducts in nasal and oral mucosa of rats treated chronically with enantiomers of N'-nitrosonornicotine. Chem Res Toxicol. 2009 May;22(5):949-56. doi: 10.1021/tx900040j.</citation>
    <PMID>19405515</PMID>
  </reference>
  <reference>
    <citation>Zhang S, Wang M, Villalta PW, Lindgren BR, Upadhyaya P, Lao Y, Hecht SS. Analysis of pyridyloxobutyl and pyridylhydroxybutyl DNA adducts in extrahepatic tissues of F344 rats treated chronically with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and enantiomers of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Chem Res Toxicol. 2009 May;22(5):926-36. doi: 10.1021/tx900015d.</citation>
    <PMID>19358518</PMID>
  </reference>
  <reference>
    <citation>Lao Y, Yu N, Kassie F, Villalta PW, Hecht SS. Analysis of pyridyloxobutyl DNA adducts in F344 rats chronically treated with (R)- and (S)-N'-nitrosonornicotine. Chem Res Toxicol. 2007 Feb;20(2):246-56.</citation>
    <PMID>17305408</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>April 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2015</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tobacco toxicants</keyword>
  <keyword>smokeless tobacco</keyword>
  <keyword>nitrosamines</keyword>
  <keyword>tobacco specific nitrosamines (TSNAs)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lobeline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

